Heart tissue study aims to unlock how diabetes drugs help failing hearts
NCT ID NCT05830760
First seen Jan 08, 2026 · Last updated Jun 13, 2026 · Updated 26 times
Summary
This study was designed to measure a protein called SGLT2 in heart muscle samples taken during aortic valve replacement surgery. Researchers planned to compare patients with and without diastolic heart failure to understand why gliflozine drugs (like empagliflozin) benefit the heart. The study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France
Conditions
Explore the condition pages connected to this study.